美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Medicus Pharma Ltd.

0.2594

+0.00200.78%

成交量：7.29萬

成交額：1.85萬

市值：1,638.91萬

市盈率：-0.16

高：0.2600

開：0.2536

低：0.2536

收：0.2574

52周最高：3.05

52周最低：0.2425

股本：6,318.06萬

流通股本：5,690.10萬

量比：16.81

換手率：0.13%

股息：- -

股息率：- -

每股收益(TTM):-1.6597

每股收益(LYR):-2.7356

淨資產收益率：-7446.11%

總資產收益率：-110.67%

市淨率：-9.29

市盈率(LYR):-0.09

資料載入中...

總覽公司新聞資訊公告

新聞稿：Medicus Pharma 任命 Faisal Mehmud 博士為英國子公司 Antev Limited 首席執行官

Medicus Pharma任命DR. Faisal Mehmud為英國Antev Limited首席執行官

Medicus Pharma獲阿聯酋衞生部門批准，推進Teverelix Precision-E2 2a期臨床研究

Medicus Pharma 獲FDA批准：針對戈林綜合徵患者的Skinject®關鍵註冊研究可啓動

Medicus Pharma獲FDA積極反饋及中心IRB批准，開展優化版Teverelix®治療急性尿瀦留二期新研究

Medicus Pharma宣佈向美國食品藥品監督管理局提交Skinject®用於戈林綜合徵的罕見兒科疾病認定申請

Medicus Pharma啓動基於阿聯酋基因組計劃的突破性Teverelix®治療子宮內膜異位症的Precision-E2 IIa期研究

Medicus Pharma推進Teverelix®項目進入註冊開發階段，針對高心血管風險前列腺癌患者完成關鍵歐洲提交

Medicus Pharma公布預設擴展二期Sknjct-003數據分析結果顯示顯著劑量效應

Medicus Pharma Ltd. 旗下D-Mna展現良好安全性特徵未出現藥物相關嚴重不良事件

Medicus製藥公司提交SEC文件：擬通過代理機構發行不超過5000萬美元普通股

Medicus Pharma向美國FDA提交Skinject®治療基底細胞痣綜合徵的孤兒藥認定申請

Medicus醫藥公司向美國FDA提交Teverelix治療急性尿瀦留的優化二期研究方案

Medicus Pharma：二期研究為「概念驗證」探索性研究，主要聚焦實現顯著臨床（視覺）清除

Medicus Pharma業務更新電話會議將重點展示Skinject二期研究80%總體緩解率及AI驅動藥物開發計劃

Medicus醫藥公司宣佈皮膚注射劑二期首席研究員兼意見領袖Babar K. Rao博士將於3月26日業務更新網絡直播中解讀積極臨床數據

Siga Technologies Inc.盤中異動股價大跌5.17%報5.50美元

Prf Technologies Ltd.盤中異動急速跳水8.00%報2.53美元

Medicus Pharma公布二期Sknjct-003試驗積極頂線數據：200微克組第57天實現73%臨床清除率與40%組織學清除率

美國OTC市場Gsk Plc盤中異動股價大跌5.77%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/MDCX/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","market":"US","secType":"STK","nameCN":"Medicus Pharma Ltd.","latestPrice":0.2594,"timestamp":1787664602198,"preClose":0.2574,"halted":0,"volume":72862,"delay":0,"changeRate":0.007770007770007776,"floatShares":56901000,"shares":63180610,"eps":-1.659689,"marketStatus":"交易中","change":0.002,"latestTime":"08-25 09:30:15 EDT","open":0.2536,"high":0.26,"low":0.2536,"amount":18540.68019152,"amplitude":0.024864,"askPrice":0.2648,"askSize":1047,"bidPrice":0.25,"bidSize":63822,"shortable":3,"etf":0,"ttmEps":-1.659689,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"listingDate":1731560400000,"exchange":"NASDAQ","adjPreClose":0.2574,"preHourTrading":{"tag":"盘前","latestPrice":0.2648,"preClose":0.2574,"latestTime":"09:10 EDT","volume":1664,"amount":439.8046016,"timestamp":1787663450143,"change":0.0074,"changeRate":0.028749,"amplitude":0.021756},"postHourTrading":{"tag":"盘后","latestPrice":0.2599,"preClose":0.2574,"latestTime":"19:38 EDT","volume":11232,"amount":2903.86234,"timestamp":1787614682951,"change":0.0025,"changeRate":0.009713,"amplitude":0.02331},"volumeRatio":16.806754},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","floatShares":56901000,"roa":"-110.67%","roe":"-7446.11%","lyrEps":-2.735593,"volumeRatio":16.806754,"shares":63180610,"dividePrice":0,"high":0.26,"amplitude":0.024864,"preClose":0.2574,"low":0.2536,"week52Low":0.2425,"pbRate":"-9.29","week52High":3.05,"institutionHeld":0,"latestPrice":0.2594,"committee":0.96772,"eps":-1.659689,"divideRate":0,"volume":72862,"delay":0,"ttmEps":-1.659689,"open":0.2536,"prevYearClose":1.53,"prevWeekClose":0.2718,"prevMonthClose":0.2752,"prevQuarterClose":0.4463,"fiveDayClose":0.2633,"twentyDayClose":0.28,"sixtyDayClose":0.379},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"MDCX","fiscalQuarterEnding":"2026/06","expectedEps":-0.14,"name":null,"time":"盤後","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2026-05-14","symbol":"MDCX","fiscalQuarterEnding":"2026/03","expectedEps":-0.18,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-0.31},{"market":"US","date":"2026-03-25","symbol":"MDCX","fiscalQuarterEnding":"2025/12","expectedEps":-0.32,"name":null,"time":"盤後","type":"earning","dateTimestamp":1774411200000,"reportTimeType":"post","actualEps":-0.82},{"date":"2025-11-14","symbol":"MDCX","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1763154000000,"name":null,"time":"盤後","dateTimestamp":1763096400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1785470400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MDCX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MDCX","date":"2026-08-24","current":-0.155089,"percent":0.899598,"low":-3.23298,"twenty":-2.195011,"median":-0.789709,"eighty":-0.353572,"high":-0.235266,"avg":-1.119508,"sd":0.953327,"marketCap":17172489},"quantilePoints":[{"date":"2025-08-29","current":-2.084531,"twenty":-2.272139,"median":-2.126221,"eighty":-2.109545,"marketCap":35632532},{"date":"2025-09-05","current":-1.907346,"twenty":-2.205434,"median":-2.115799,"eighty":-2.053263,"marketCap":32603766},{"date":"2025-09-12","current":-2.345097,"twenty":-2.211687,"median":-2.12101,"eighty":-2.053263,"marketCap":40086598},{"date":"2025-09-19","current":-2.532705,"twenty":-2.511859,"median":-2.178335,"eighty":-2.080362,"marketCap":43293526},{"date":"2025-09-26","current":-2.817408,"twenty":-2.759151,"median":-2.287772,"eighty":-2.103292,"marketCap":48160186},{"date":"2025-10-03","current":-3.005474,"twenty":-2.869667,"median":-2.511859,"eighty":-2.115799,"marketCap":51374941},{"date":"2025-10-10","current":-3.005474,"twenty":-2.994879,"median":-2.558762,"eighty":-2.122052,"marketCap":51374941},{"date":"2025-10-17","current":-2.885734,"twenty":-2.976858,"median":-2.720313,"eighty":-2.151236,"marketCap":49328130},{"date":"2025-10-24","current":-2.909682,"twenty":-2.974342,"median":-2.774974,"eighty":-2.174166,"marketCap":49737492},{"date":"2025-10-31","current":-2.957578,"twenty":-2.974342,"median":-2.817408,"eighty":-2.178335,"marketCap":50556216},{"date":"2025-11-07","current":-2.897708,"twenty":-2.962368,"median":-2.809662,"eighty":-2.228364,"marketCap":49532811},{"date":"2025-11-14","current":-2.706124,"twenty":-2.950394,"median":-2.817408,"eighty":-2.292984,"marketCap":46257915},{"date":"2025-11-21","current":-1.28141,"twenty":-2.950394,"median":-2.789942,"eighty":-2.178335,"marketCap":44939453},{"date":"2025-11-28","current":-1.355609,"twenty":-2.936025,"median":-2.763,"eighty":-2.119968,"marketCap":48464116},{"date":"2025-12-05","current":-1.183077,"twenty":-2.916866,"median":-2.742046,"eighty":-2.04284,"marketCap":42295956},{"date":"2025-12-12","current":-1.201563,"twenty":-2.904892,"median":-2.700137,"eighty":-1.376181,"marketCap":42956830},{"date":"2025-12-19","current":-1.022869,"twenty":-2.897708,"median":-2.63428,"eighty":-1.31987,"marketCap":36568379},{"date":"2025-12-26","current":-0.955088,"twenty":-2.897553,"median":-2.584818,"eighty":-1.266827,"marketCap":34145173},{"date":"2026-01-02","current":-1.074791,"twenty":-2.896932,"median":-2.511859,"eighty":-1.220048,"marketCap":38424640},{"date":"2026-01-09","current":-1.095865,"twenty":-2.885734,"median":-2.329463,"eighty":-1.179996,"marketCap":39178064},{"date":"2026-01-16","current":-0.976444,"twenty":-2.885734,"median":-2.178335,"eighty":-1.123965,"marketCap":34908660},{"date":"2026-01-23","current":-0.94132,"twenty":-2.866576,"median":-2.167912,"eighty":-1.101485,"marketCap":33652952},{"date":"2026-01-30","current":-0.878097,"twenty":-2.861786,"median":-2.115799,"eighty":-1.061072,"marketCap":31392680},{"date":"2026-02-06","current":-0.765701,"twenty":-2.861786,"median":-2.074108,"eighty":-1.022014,"marketCap":27374416},{"date":"2026-02-13","current":-0.709738,"twenty":-2.853549,"median":-1.933403,"eighty":-0.974021,"marketCap":25373688},{"date":"2026-02-20","current":-0.786136,"twenty":-2.850483,"median":-1.381324,"eighty":-0.961937,"marketCap":28104981},{"date":"2026-02-27","current":-0.97195,"twenty":-2.849812,"median":-1.344224,"eighty":-0.949581,"marketCap":34747976},{"date":"2026-03-06","current":-0.484474,"twenty":-2.849812,"median":-1.300152,"eighty":-0.949581,"marketCap":17320333},{"date":"2026-03-13","current":-0.412761,"twenty":-2.835443,"median":-1.263181,"eighty":-0.891018,"marketCap":14756541},{"date":"2026-03-20","current":-0.412761,"twenty":-2.825864,"median":-1.220048,"eighty":-0.847322,"marketCap":14756541},{"date":"2026-03-27","current":-0.387698,"twenty":-2.82079,"median":-1.201563,"eighty":-0.836077,"marketCap":18330934},{"date":"2026-04-02","current":-0.349652,"twenty":-2.811211,"median":-1.179996,"eighty":-0.820403,"marketCap":16532085},{"date":"2026-04-10","current":-0.367967,"twenty":-2.792337,"median":-1.125793,"eighty":-0.786136,"marketCap":17398052},{"date":"2026-04-17","current":-0.250001,"twenty":-2.775573,"median":-1.109135,"eighty":-0.744685,"marketCap":11820441},{"date":"2026-04-24","current":-0.276475,"twenty":-2.764797,"median":-1.099378,"eighty":-0.508201,"marketCap":13072156},{"date":"2026-05-01","current":-0.235266,"twenty":-2.75402,"median":-1.088841,"eighty":-0.417566,"marketCap":11123732},{"date":"2026-05-08","current":-0.277717,"twenty":-2.74923,"median":-1.069002,"eighty":-0.412761,"marketCap":13130880},{"date":"2026-05-15","current":-0.393186,"twenty":-2.733353,"median":-1.041354,"eighty":-0.401798,"marketCap":18590424},{"date":"2026-05-22","current":-0.308017,"twenty":-2.714637,"median":-1.024243,"eighty":-0.38811,"marketCap":15777036},{"date":"2026-05-29","current":-0.354651,"twenty":-2.703729,"median":-1.018593,"eighty":-0.376126,"marketCap":18165658},{"date":"2026-06-05","current":-0.402361,"twenty":-2.691755,"median":-0.976444,"eighty":-0.374724,"marketCap":20609444},{"date":"2026-06-12","current":-0.35842,"twenty":-2.672597,"median":-0.968141,"eighty":-0.372398,"marketCap":18358733},{"date":"2026-06-18","current":-0.378775,"twenty":-2.63428,"median":-0.962395,"eighty":-0.367967,"marketCap":19401342},{"date":"2026-06-26","current":-0.492235,"twenty":-2.63428,"median":-0.955088,"eighty":-0.371628,"marketCap":25212882},{"date":"2026-07-02","current":-0.442458,"twenty":-2.59471,"median":-0.94132,"eighty":-0.37203,"marketCap":22663265},{"date":"2026-07-10","current":-0.467347,"twenty":-2.543128,"median":-0.915037,"eighty":-0.3732,"marketCap":23938074},{"date":"2026-07-17","current":-0.449095,"twenty":-2.516028,"median":-0.871896,"eighty":-0.374395,"marketCap":23003214},{"date":"2026-07-24","current":-0.424981,"twenty":-2.511859,"median":-0.846653,"eighty":-0.374627,"marketCap":21768066},{"date":"2026-07-31","current":-0.290474,"twenty":-2.411802,"median":-0.843141,"eighty":-0.371929,"marketCap":14878433},{"date":"2026-08-07","current":-0.34025,"twenty":-2.326336,"median":-0.835949,"eighty":-0.363051,"marketCap":17428051},{"date":"2026-08-14","current":-0.353971,"twenty":-2.282561,"median":-0.821824,"eighty":-0.360424,"marketCap":20056990},{"date":"2026-08-21","current":-0.30351,"twenty":-2.211687,"median":-0.793282,"eighty":-0.354379,"marketCap":17197762},{"date":"2026-08-24","current":-0.303064,"twenty":-2.195011,"median":-0.789709,"eighty":-0.353572,"marketCap":17172489}],"updateTime":1787653688197},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1107772972","title":"新聞稿：Medicus Pharma 任命 Faisal Mehmud 博士為英國子公司 Antev Limited 首席執行官","url":"https://stock-news.laohu8.com/highlight/detail?id=1107772972","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107772972?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 19:33","pubTimestamp":1785756837,"startTime":"0","endTime":"0","summary":"费城，2026年8月3日——生物科技与生命科学公司 Medicus Pharma Ltd.今日宣布，任命Faisal Mehmud医学博士、皇家内科医师学会会员为英国子公司Antev Limited的首席执行官，自2026年8月30日起生效。该公司专注于推进新型且潜在颠覆性治疗资产的临床开发项目。Mehmud博士将继续担任Medicus的首席医疗官和Antev的联合主席。此次任命进一步加强了Medicus的整合领导架构。Mehmud博士接替了Amit Kohli，后者自2025年8月29日Medicus完成对Antev的收购以来一直担任临时首席执行官。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","BK4211","BK4139","MDCX","BCC","BK4205","BK4528","BK4022","BK4232","UK","BK4567","R","UBCP","MRCP","BK4233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127932291","title":"Medicus Pharma任命DR. Faisal Mehmud為英國Antev Limited首席執行官","url":"https://stock-news.laohu8.com/highlight/detail?id=1127932291","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127932291?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 19:31","pubTimestamp":1785756684,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.（简称Medicus Pharma）正式宣布，已任命DR. Faisal Mehmud担任其旗下位于英国的子公司Antev Limited的首席执行官一职。这一重要人事变动，标志着公司在全球战略布局中迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177582386","title":"Medicus Pharma獲阿聯酋衞生部門批准，推進Teverelix Precision-E2 2a期臨床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1177582386","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177582386?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 19:31","pubTimestamp":1785497475,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.宣布，阿联酋卫生部门已正式批准其开展Teverelix的Precision-E2 2a期临床研究。这一授权标志着该药物研发进程中的重要里程碑。获批的临床试验将聚焦于评估Teverelix的疗效与安全性，为后续研究奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149302811","title":"Medicus Pharma 獲FDA批准：針對戈林綜合徵患者的Skinject®關鍵註冊研究可啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=1149302811","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149302811?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 20:18","pubTimestamp":1785154690,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.（MDCX）近日迎来重大里程碑——美国食品药品监督管理局（FDA）已正式发出“研究可推进”函件，为其针对戈林综合征患者的NDA注册性Skinject®研究亮起绿灯。这一关键进展，标志着该药物的临床开发迈入新阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153699376","title":"Medicus Pharma獲FDA積極反饋及中心IRB批准，開展優化版Teverelix®治療急性尿瀦留二期新研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1153699376","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153699376?lang=zh_tw&edition=fundamental","pubTime":"2026-07-16 19:31","pubTimestamp":1784201518,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.宣布，其针对急性尿潴留的优化版Teverelix®二期新研究已获得美国食品药品监督管理局（FDA）的积极反馈以及中心机构审查委员会（IRB）的批准。这一关键进展标志着该创新疗法向临床开发迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126634681","title":"Medicus Pharma宣佈向美國食品藥品監督管理局提交Skinject®用於戈林綜合徵的罕見兒科疾病認定申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1126634681","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126634681?lang=zh_tw&edition=fundamental","pubTime":"2026-06-15 19:31","pubTimestamp":1781523074,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.（MDCX）已正式向美国食品药品监督管理局（FDA）提交申请，为其在研产品Skinject®寻求戈林综合征适应症的罕见儿科疾病认定。这一认定若获批准，将有望为患有此种罕见遗传性皮肤疾病的儿童患者带来新的治疗希望，并可能使公司在后续的研发与商业化进程中享有相应的政策激励。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103137641","title":"Medicus Pharma啓動基於阿聯酋基因組計劃的突破性Teverelix®治療子宮內膜異位症的Precision-E2 IIa期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1103137641","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103137641?lang=zh_tw&edition=fundamental","pubTime":"2026-06-11 19:31","pubTimestamp":1781177506,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. (MDCX) 宣布启动一项具有开创性的Precision-E2 IIa期临床研究，该研究将利用阿联酋基因组计划的数据，评估其候选药物Teverelix®在治疗子宫内膜异位症方面的疗效与安全性。这项研究标志着该公司在精准医疗领域迈出了重要一步，旨在通过基因组信息为患者提供更个体化的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110064382","title":"Medicus Pharma推進Teverelix®項目進入註冊開發階段，針對高心血管風險前列腺癌患者完成關鍵歐洲提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1110064382","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110064382?lang=zh_tw&edition=fundamental","pubTime":"2026-06-08 19:33","pubTimestamp":1780918414,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. 已将其Teverelix项目推进至注册开发阶段，旨在针对伴有高心血管风险的前列腺癌患者。这一进展的关键标志是公司已向欧洲监管机构提交了关键文件。Teverelix项目专注于满足这一特定患者群体的医疗需求，他们因心血管并发症风险较高，在治疗选择上面临更大挑战。下一步，公司将与监管机构密切合作，以确定后续的开发路径。这一战略举措有望为Medicus Pharma在该治疗领域建立重要地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113733033","title":"Medicus Pharma公布預設擴展二期Sknjct-003數據分析結果 顯示顯著劑量效應","url":"https://stock-news.laohu8.com/highlight/detail?id=1113733033","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113733033?lang=zh_tw&edition=fundamental","pubTime":"2026-05-06 19:37","pubTimestamp":1778067449,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.最新披露的预设扩展二期临床试验Sknjct-003数据分析结果证实，其研究药物存在明确的剂量-效应关系。该数据进一步验证了治疗方案的有效性，为后续临床开发提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107238761","title":"Medicus Pharma Ltd. 旗下D-Mna展現良好安全性特徵 未出現藥物相關嚴重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1107238761","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107238761?lang=zh_tw&edition=fundamental","pubTime":"2026-05-06 19:34","pubTimestamp":1778067254,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. 近日公布其研究药物D-Mna的临床试验数据，结果显示该药物表现出良好的安全性特征。在整个试验过程中，未观察到任何与药物相关的严重不良事件。\n这一积极数据为D-Mna的后续临床开发奠定了坚实基础，凸显了其在安全性方面的显著优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169937282","title":"Medicus製藥公司提交SEC文件：擬通過代理機構發行不超過5000萬美元普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1169937282","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169937282?lang=zh_tw&edition=fundamental","pubTime":"2026-04-24 05:13","pubTimestamp":1776978807,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的文件显示，Medicus制药有限公司计划通过指定代理机构，以公开发行的方式出售普通股，募集资金总额最高可达5000万美元。\n该文件表明，公司可能根据市场条件、股价波动等因素，一次或分多次进行股份发售。此次融资方案将为Medicus制药提供额外的运营资本，以支持其业务发展和战略计划的推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128375198","title":"Medicus Pharma向美國FDA提交Skinject®治療基底細胞痣綜合徵的孤兒藥認定申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1128375198","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128375198?lang=zh_tw&edition=fundamental","pubTime":"2026-04-17 19:34","pubTimestamp":1776425694,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. (MDCX) 已正式向美国食品药品监督管理局（FDA）提交申请，为其创新药物Skinject®寻求孤儿药认定，适应症为基底细胞痣综合征（Gorlin Syndrome）。\n此举标志着该公司在推进该罕见病治疗方案方面迈出了关键一步。孤儿药认定旨在激励针对影响少数人群的罕见疾病的药物研发。若获得批准，将为Skinject®后续的临床开发及商业化带来潜在优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176135876","title":"Medicus醫藥公司向美國FDA提交Teverelix治療急性尿瀦留的優化二期研究方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1176135876","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176135876?lang=zh_tw&edition=fundamental","pubTime":"2026-04-06 19:31","pubTimestamp":1775475075,"startTime":"0","endTime":"0","summary":"Medicus医药公司（Medicus Pharma Ltd.）已向美国食品药品监督管理局（FDA）提交了其候选药物Teverelix用于治疗急性尿潴留的优化二期临床试验方案。此举标志着该药物在临床开发路径上迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111663718","title":"Medicus Pharma：二期研究為「概念驗證」探索性研究，主要聚焦實現顯著臨床（視覺）清除","url":"https://stock-news.laohu8.com/highlight/detail?id=1111663718","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111663718?lang=zh_tw&edition=fundamental","pubTime":"2026-04-01 19:33","pubTimestamp":1775043222,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. 近期公布，其二期研究定位为一项“概念验证”性质的探索性研究。该研究的核心目标在于实现具有临床意义的视觉清除效果，为后续开发提供关键数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160017302","title":"Medicus Pharma業務更新電話會議將重點展示Skinject二期研究80%總體緩解率及AI驅動藥物開發計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=1160017302","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160017302?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 19:31","pubTimestamp":1774524676,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.即将召开业务更新电话会议，届时将重点公布其Skinject二期临床研究取得的突破性进展——该试验显示出高达80%的总体缓解率。此外，公司还将详细介绍其基于Agentic人工智能技术的药物开发战略规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128433525","title":"Medicus醫藥公司宣佈皮膚注射劑二期首席研究員兼意見領袖Babar K. Rao博士將於3月26日業務更新網絡直播中解讀積極臨床數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1128433525","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128433525?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 19:32","pubTimestamp":1773660769,"startTime":"0","endTime":"0","summary":"Medicus医药公司近日宣布，其皮肤疾病治疗产品Skinject®二期临床试验的首席研究员兼关键意见领袖Babar K. Rao博士（医学博士、美国皮肤科学院院士）将于3月26日的业务更新网络直播中对最新阳性数据进行临床解读。此次直播将深入解析试验数据的临床意义与价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618953047","title":"Siga Technologies Inc.盤中異動 股價大跌5.17%報5.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618953047","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618953047?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 22:00","pubTimestamp":1773064835,"startTime":"0","endTime":"0","summary":"北京时间2026年03月09日22时00分，Siga Technologies Inc.股票出现波动，股价急速下挫5.17%。截至发稿，该股报5.50美元/股，成交量7.3733万股，换手率0.10%，振幅3.28%。Siga Technologies Inc.股票所在的制药行业中，整体跌幅为0.82%。Siga Technologies Inc.公司简介：西佳科技有限公司是一家专注于健康安全市场的商业阶段制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030922003695461cf2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030922003695461cf2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MDCX","BK4007","SIGA","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617658389","title":"Prf Technologies Ltd.盤中異動 急速跳水8.00%報2.53美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617658389","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617658389?lang=zh_tw&edition=fundamental","pubTime":"2026-03-06 22:59","pubTimestamp":1772809178,"startTime":"0","endTime":"0","summary":"北京时间2026年03月06日22时59分，Prf Technologies Ltd.股票出现异动，股价急速跳水8.00%。截至发稿，该股报2.53美元/股，成交量2434股，换手率0.31%，振幅4.91%。Prf Technologies Ltd.股票所在的制药行业中，整体跌幅为1.85%。Prf Technologies Ltd.公司简介：PainReform Ltd是一家多元化的平台型企业，涵盖特种制药、药物输送技术以及基于人工智能的可再生能源分析等领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306225938a6ab4be6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306225938a6ab4be6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PRFX","BK4139","MDCX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177064497","title":"Medicus Pharma公布二期Sknjct-003試驗積極頂線數據：200微克組第57天實現73%臨床清除率與40%組織學清除率","url":"https://stock-news.laohu8.com/highlight/detail?id=1177064497","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177064497?lang=zh_tw&edition=fundamental","pubTime":"2026-03-05 20:33","pubTimestamp":1772714036,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd.近日披露了其二期临床试验Sknjct-003的顶线研究结果，数据表现亮眼。在200微克剂量组中，第57天的评估显示，患者达到73%的临床清除率，同时组织学清除率也达到40%。这一数据为后续临床开发提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613518237","title":"美國OTC市場Gsk Plc盤中異動 股價大跌5.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613518237","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613518237?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 22:51","pubTimestamp":1771858316,"startTime":"0","endTime":"0","summary":"北京时间2026年02月23日22时51分，美国OTC市场Gsk Plc股票出现波动，股价急速跳水5.77%。截至发稿，该股报29.40美元/股，成交量970股，换手率0.00%，振幅0.00%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。美国OTC市场Gsk Plc股票所在的制药行业中，整体涨幅为1.91%。美国OTC市场Gsk Plc公司简介：在制药行业，葛兰素史克是总销售额最大的公司之一。葛兰素史克利用合资企业在艾滋病毒等特定市场获得额外的规模。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602232251569541aee0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602232251569541aee0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MDCX","BK4007","GLAXF"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}]}}